{"id":534134,"date":"2010-04-19T12:35:01","date_gmt":"2010-04-19T16:35:01","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=74430"},"modified":"2010-04-19T12:35:01","modified_gmt":"2010-04-19T16:35:01","slug":"javelin-pharma-dumps-myriad-for-hospira","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/534134","title":{"rendered":"Javelin Pharma Dumps Myriad for Hospira"},"content":{"rendered":"\n
Life Sciences<\/a>, Drugs<\/a>, Mergers<\/a><\/div>\n

\t\tRyan McBride wrote:<\/strong><\/p>\n

Javelin Pharmaceuticals (AMEX:JAV<\/a>), a Cambridge, MA-based developer of pain treatments, reports today that it has nixed<\/a> its merger agreement with Myriad Pharmaceuticals (NASDAQ:MYRX<\/a>) and accepted<\/a> a $145 million buyout offer from the specialty drugmaker Hospira. Lake Forest, IL-based Hospira (NYSE:HSP<\/a>) plans to begin its tender offer to acquire shares of Javelin’s common stock on Wednesday for $2.20 per share. Hospira has also agreed to provide Javelin with three loan facilities of $4.5 million, $8.3 million, and $4.4 million for Javelin to fund operations, to repay loans from Salt Like City-based Myriad, and to cover fees and expenses related to the termination of Javelin’s previous deal with Myriad, respectively.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, Drugs, Mergers Ryan McBride wrote: Javelin Pharmaceuticals (AMEX:JAV), a Cambridge, MA-based developer of pain treatments, reports today that it has nixed its merger agreement with Myriad Pharmaceuticals (NASDAQ:MYRX) and accepted a $145 million buyout offer from the specialty drugmaker Hospira. Lake Forest, IL-based Hospira (NYSE:HSP) plans to begin its tender offer to acquire […]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-534134","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=534134"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534134\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=534134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=534134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=534134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}